We are excited to announce three new features now available on PPMD's DuchenneConnect! These tools are meant to help you in your journey as you gather information around potential research studies and potential new exon skipping therapies.
Keep Your DuchenneConnect Profile Updated
Before we introduce you to these exciting new tools, we want to remind you how critical it is to keep your DuchenneConnect profile updated. And if you’re not registered in DuchenneConnect, make today the day!
One of DuchenneConnect’s most important roles is partnering directly with researchers to help them recruit for trials. If it looks like you may be a good fit for a trial (based on the answers to your medical history surveys in DuchenneConnect), you will receive an email from us describing the trial and how to get more information.
Receiving an email from us about a trial isn’t a guarantee that you will qualify for that trial, but it does mean that you may meet some of the main inclusion criteria. As always, if you have questions about any trial we encourage you to contact the coordinator for that study or reach out to us at DuchenneConnect.
Meet the New Tools!
Here is a brief summary of our three new tools that we hope will make the process of finding information about clinical trials as easy as possible:
Your Number One Resource
While we believe these tools will help alleviate some of the overwhelming research parents and people with Duchenne undertake in an effort to research what trials they may qualify for, PPMD's DuchenneConnect team is still your number one resource to navigate this complex world.
If you have questions or concerns, please don’t hesitate to contact us via email at firstname.lastname@example.org or phone at 888-520-8675. You are all important to us and by being a member of DuchenneConnect and keeping your information updated, you are helping in our fight to end Duchenne.
If you haven’t joined DuchenneConnect, we encourage you to do so! We welcome all people with Duchenne, Becker and women and girls who are carriers.